| Peanut Allergy |
1 |
1 |
| Allergy |
0 |
0.74 |
| Food Allergy |
0 |
0.85 |
| Child |
0 |
0.95 |
| Asthma |
0 |
0.9 |
| Health Care Reform |
0 |
0.24 |
| Immunotherapy |
0 |
0.2 |
| Outpatient Clinic |
0 |
0.2 |
| Biologic Therapy |
0 |
0.19 |
| Clinical Research |
0 |
0.16 |
| Immunology |
0 |
0.16 |
| Patient Safety |
0 |
0.15 |
| Revenue and Practice Management |
0 |
0.14 |
| Board Certification |
0 |
0.12 |
| Food and Drug Administration (FDA) |
0 |
0.12 |
| Adverse Effects |
0 |
0.08 |
| Arkansas |
0 |
0.08 |
| Brachial |
0 |
0.08 |
| Europe |
0 |
0.08 |
| Grant |
0 |
0.08 |
| Immune Tolerance |
0 |
0.08 |
| Social Determinants of Health |
0 |
0.08 |
| Tolerance |
0 |
0.08 |
| Risk Evaluation and Mitigation Strategies |
0 |
0.06 |
| Anaplastic Lymphoma Kinase |
0 |
0.04 |
| Blood |
0 |
0.04 |
| Canada |
0 |
0.04 |
| Clinical Guidelines |
0 |
0.04 |
| Geriatrics |
0 |
0.04 |
| Health Care Economics |
0 |
0.04 |
| Health Care Quality, Access, and Evaluation |
0 |
0.04 |
| Hospital |
0 |
0.04 |
| Insurance |
0 |
0.04 |
| Office Visits |
0 |
0.04 |
| Professional Societies |
0 |
0.04 |
| Third Space |
0 |
0.04 |